CLIA-Validated PBMC Mass Cytometry Immune Profiling Assay

Clinical trials-grade immunophenotyping with 40+ markers for peripheral blood immune detection

Identify immune biomarkers for dose selection, mechanism of action, and pharmacodynamic studies in your clinical trials.

Analyze up to 840 immune cell subsets and states with our 41-marker mass cytometry panel. Accurate subset measurements with <10% coefficient of variation for all major immune cell types.

Total Average Coefficient of Variations:

  • Intra-Run Precision: 3.52%
  • Inter-Run Precision: 6.66%
  • Inter-Operator Precision:
    • Donor 1: 4.83%
    • Donor 2: 7.36%

Validated with cryopreserved human PBMC.

Download Validation Report

Up to 800+ Immune Subsets and States Analyzed

Page Anchor: #pbmc-mass-cytometry – Not Visible On Front

Expertly Designed Human Pan-Immune PBMC Panel

The TokuProfile Standard Human Pan-Immune PBMC panel includes:

  • Markers to identify every major immune cell population and subsets
  • Expression of key co-stimulatory and co-inhibitory molecules that regulate cell function
  • Markers of recent activation and effector function
Download our 41-marker panel

  • T cells

    CD3
    Total T cells
    CD4
    CD4+ T cells
    CD8a
    CD8+ T cells
    CD27
    Maturation
    CD45RA
    Naive/Memory
    CCR7 (CD197)
    Naive/Memory
    Foxp3
    Treg
    CD25
    Treg, activation
    CD127
    T cell subsets
    T-bet
    T cell subsets
    CD38
    Maturation
    CD69
    Early Activation
    HLA-DR
    Activation
    CD56
    NKT, T cell subsets
    gdTCR
    gdT cells
    CTLA-4 (CD152)
    Checkpoint
    PD-1
    Checkpoint
    TIM-3
    Checkpoint
    TIGIT
    Checkpoint
    LAG3
    Checkpoint
    CD57
    Senescence
    KLRG-1
    Senescence
    Granzyme B
    Effector
    CD95
    Stem cell memory
    CD39
    Tumor specific
    CD28
    Co-stimulation, Maturation
    CD161
    Inhibitory Receptor
    ICOS
    Checkpoint

  • B cells

    CD19
    Total B cells
    CD25
    Activation
    CD27
    Naive/Memory
    CD38
    Naive/Memory
    HLA-DR
    Antigen presentation

  • NK cells

    CD56
    NK cell subsets
    CD16
    NK cell subsets
    CD8a
    NK cell subsets
    CD38
    Activation
    T-bet
    Maturation
    Granzyme B
    Effector

  • Myeloid cells

    CD11b
    Monocytes, macrophages
    CD11c
    Monocytes, macrophages, DCs
    CD14
    Monocyte subsets, Macrophages
    CD16
    Monocyte subsets
    CD33
    Total myeloid
    CD123
    pDC
    PD-L1
    Checkpoint ligand
    HLA-DR
    Antigen presentation
    LOX-1
    PMN-MDSCs

  • Granulocytes

    Whole blood only
    CD66b
    Granulocytes
    CD11b
    Neutrophils
    CD16
    Neutrophils
    CD15
    Neutrophils
    CD123
    Basophils

  • General

    CD45
    Total immune cells
    KI67
    Proliferation
    DNA
    Singlets
    Live/Dead
    Viability
    IgG4
    Nivo/Pembro
Page Anchor: #pbmc-mass-cytometry-validation – Not Visible On Front
CLIA Validation Data

CLIA Validation Data

Mass Cytometry Assay for Pan-Immune Profiling of PBMCs

Fill out the form below to access our CLIA Validation plan, report, and data and SOPs.